PubMed:32522282 / 206-686 JSONTXT

{"project":"LitCovid-OGER-BB","denotations":[{"id":"T6","span":{"begin":99,"end":109},"obj":"CHEBI:33282"},{"id":"T7","span":{"begin":99,"end":109},"obj":"CHEBI:33282"},{"id":"T8","span":{"begin":110,"end":122},"obj":"CHEBI:2955"},{"id":"T9","span":{"begin":110,"end":122},"obj":"CHEBI:2955"},{"id":"T10","span":{"begin":110,"end":122},"obj":"DG_6"},{"id":"T11","span":{"begin":127,"end":145},"obj":"CHEBI:5801"},{"id":"T12","span":{"begin":127,"end":145},"obj":"CHEBI:5801"},{"id":"T13","span":{"begin":127,"end":145},"obj":"DG_20"},{"id":"T14","span":{"begin":168,"end":174},"obj":"UBERON:0002405"},{"id":"T15","span":{"begin":175,"end":185},"obj":"GO:0065007"},{"id":"T16","span":{"begin":307,"end":315},"obj":"SP_7"},{"id":"T17","span":{"begin":450,"end":469},"obj":"UBERON:0007221"},{"id":"T18","span":{"begin":474,"end":479},"obj":"GO:0016265"}],"namespaces":[{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"}],"text":"The aim of this randomised GCP-controlled trial is to clarify whether combination therapy with the antibiotic azithromycin and hydroxychloroquine via anti-inflammation/immune modulation, antiviral efficacy and pre-emptive treatment of supra-infections can shorten hospitalisation duration for patients with COVID-19 (measured as \"days alive and out of hospital\" as the primary outcome), reduce the risk of non- invasive ventilation, treatment in the intensive care unit and death."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T2","span":{"begin":155,"end":167},"obj":"Disease"},{"id":"T3","span":{"begin":241,"end":251},"obj":"Disease"},{"id":"T4","span":{"begin":307,"end":315},"obj":"Disease"}],"attributes":[{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"The aim of this randomised GCP-controlled trial is to clarify whether combination therapy with the antibiotic azithromycin and hydroxychloroquine via anti-inflammation/immune modulation, antiviral efficacy and pre-emptive treatment of supra-infections can shorten hospitalisation duration for patients with COVID-19 (measured as \"days alive and out of hospital\" as the primary outcome), reduce the risk of non- invasive ventilation, treatment in the intensive care unit and death."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T5","span":{"begin":4,"end":7},"obj":"http://purl.obolibrary.org/obo/PR_000001343"}],"text":"The aim of this randomised GCP-controlled trial is to clarify whether combination therapy with the antibiotic azithromycin and hydroxychloroquine via anti-inflammation/immune modulation, antiviral efficacy and pre-emptive treatment of supra-infections can shorten hospitalisation duration for patients with COVID-19 (measured as \"days alive and out of hospital\" as the primary outcome), reduce the risk of non- invasive ventilation, treatment in the intensive care unit and death."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":99,"end":109},"obj":"Chemical"},{"id":"T2","span":{"begin":110,"end":122},"obj":"Chemical"},{"id":"T3","span":{"begin":127,"end":145},"obj":"Chemical"},{"id":"T4","span":{"begin":187,"end":196},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_33281"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"},{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"}],"text":"The aim of this randomised GCP-controlled trial is to clarify whether combination therapy with the antibiotic azithromycin and hydroxychloroquine via anti-inflammation/immune modulation, antiviral efficacy and pre-emptive treatment of supra-infections can shorten hospitalisation duration for patients with COVID-19 (measured as \"days alive and out of hospital\" as the primary outcome), reduce the risk of non- invasive ventilation, treatment in the intensive care unit and death."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T1","span":{"begin":155,"end":167},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"The aim of this randomised GCP-controlled trial is to clarify whether combination therapy with the antibiotic azithromycin and hydroxychloroquine via anti-inflammation/immune modulation, antiviral efficacy and pre-emptive treatment of supra-infections can shorten hospitalisation duration for patients with COVID-19 (measured as \"days alive and out of hospital\" as the primary outcome), reduce the risk of non- invasive ventilation, treatment in the intensive care unit and death."}

{"project":"LitCovid-sentences","denotations":[{"id":"T4","span":{"begin":0,"end":480},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The aim of this randomised GCP-controlled trial is to clarify whether combination therapy with the antibiotic azithromycin and hydroxychloroquine via anti-inflammation/immune modulation, antiviral efficacy and pre-emptive treatment of supra-infections can shorten hospitalisation duration for patients with COVID-19 (measured as \"days alive and out of hospital\" as the primary outcome), reduce the risk of non- invasive ventilation, treatment in the intensive care unit and death."}

{"project":"Inflammaging","denotations":[{"id":"T4","span":{"begin":0,"end":480},"obj":"Sentence"},{"id":"T4","span":{"begin":0,"end":480},"obj":"Sentence"}],"text":"The aim of this randomised GCP-controlled trial is to clarify whether combination therapy with the antibiotic azithromycin and hydroxychloroquine via anti-inflammation/immune modulation, antiviral efficacy and pre-emptive treatment of supra-infections can shorten hospitalisation duration for patients with COVID-19 (measured as \"days alive and out of hospital\" as the primary outcome), reduce the risk of non- invasive ventilation, treatment in the intensive care unit and death."}